The potential impact of pharmacogenetic testing on medication adherence

Pharmacogenomics Journal

Volumn 13, Issue 6, 2013, Pages 481-483

  Haga, S B ^a   Lapointe, N M A ^b  

^a DUKE UNIVERSITY   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

clinical care; medication adherence; outcomes; patient attitudes; pharmacogenetics

Indexed keywords

DRUG;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HEALTH DISPARITY; HUMAN; MEDICATION COMPLIANCE; PATIENT SATISFACTION; PHARMACOGENETICS; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; SELF CARE;

CHRONIC DISEASE; HUMANS; PATIENT COMPLIANCE; PHARMACOGENETICS;

EID: 84888138885     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2013.33     Document Type: Article

References (30)

1. Wang L, McLeod HL, Weinshilboum RM. Genomics and drug response. N Engl J Med 2011; 364: 1144-1153.
2. NEHI 2011, Thinking Outside the Pillbox: A System-wide Approach to Improving Patient Medication Adherence for Chronic Disease http://www. nehi. net/uploads/ full-report/pa-issue-brief-final. pdf.
3. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353: 487-497.
4. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005; 43: 521-530.
5. Fischer MA, Stedman MR, Lii J, Vogeli C, Shrank WH, Brookhart MA et al. Primary medication non-adherence: analysis of 195,930 electronic prescriptions. J Gen Intern Med 2010; 25: 284-290.
6. McGough JJ. Attention-deficit/hyperactivity disorder pharmacogenomics. Biol Psychiatry 2005; 57: 1367-1373.
7. Grant RW, Hivert M, Pandiscio JC, Florez JC, Nathan DM, Meigs JB. The clinical application of genetic testing in type 2 diabetes: a patient and physician survey. Diabetologia 2009; 52: 2299-2305.
8. Charland SL, Agatep BC, Epstein RS, Frueh FW, Herrera V, Devlin J et al. Patient knowledge of pharmacogenetic information improves adherence to statin therapy: results of the additional Kif6 risk offers better adherence to statins (Akrobats) trial. J Am Coll Cardiol 2012; 59: E1848-E1848.
9. WHO. Adherence to Long-Term Therapies: Evidence for Action. World Health Organization: Geneva, 2003http://www. who. int/chp/knowledge/publications/ adherence-report/en/.
10. Kreps GL, Villagran MM, Zhao X, McHorney CA, Ledford C, Weathers M et al. Development and validation of motivational messages to improve prescription medication adherence for patients with chronic health problems. Patient Educ Couns 2011; 83: 375-381.
11. Kripalani S, Gatti ME, Jacobson TA. Association of age, health literacy, and medication management strategies with cardiovascular medication adherence. Patient Educ Couns 2010; 81: 177-181.
12. Piette JD, Heisler M, Wagner TH. Cost-related medication underuse: do patients with chronic illnesses tell their doctors? Arch Inter Med 2004; 164: 1749-1755.
13. Lemstra M, Blackburn D, Crawley A, Fung R. Proportion and risk indicators of nonadherence to statin therapy: a meta-analysis. Can J Cardiol 2012; 28: 574-580.
14. Kripalani S, Yao X, Haynes RB. Interventions to enhance medication adherence in chronic medical conditions: a systematic review. Arch Intern Med 2007; 167: 540-550.
15. Bosworth HB, Granger BB, Mendys P, Brindis R, Burkholder R, Czajkowski SM et al. Medication adherence: a call for action. Am Heart J 2011; 162: 412-424.
16. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2008 CD000011.
17. Schroeder K, Fahey T, Ebrahim S. Interventions for improving adherence to treatment in patients with high blood pressure in ambulatory settings. Cochrane Database Syst Rev 2004; 2: CD004804.
18. van Bokhoven MA, Koch H, van der Weijden T, Grol RP, Kester AD, Rinkens PE et al. Influence of watchful waiting on satisfaction and anxiety among patients seeking care for unexplained complaints. Ann Fam Med 2009; 7: 112-120.
19. Trachtenberg F, Dugan E, Hall MA. How patients' trust relates to their involvement in medical care. J Fam Practice 2005; 54: 344-352.
20. Dowell J, Hudson H. A qualitative study of medication-taking behaviour in primary care. Fam Pract 1997; 14: 369-375.
21. Bevan JL, Lynch JA, Dubriwny TN, Harris TM, Achter PJ, Reeder AL et al. Informed lay preferences for delivery of racially varied pharmacogenomics. Genet Med 2003; 5: 393-399.
22. Shah RR, Shah DR. Personalized medicine: is it a pharmacogenetic mirage? Br J Clin Pharmacol 2012; 74: 698-721.
23. Hresko A, Haga S. Insurance coverage policies for personalized medicine. J Pers Med 2012; 2: 201-216.
24. Almarsdottir AB, Bjornsdottir I, Traulsen JM. A lay prescription for tailor-made drugs-focus group reflections on pharmacogenomics. Health Policy 2005; 71: 233-241.
25. Issa AM, Tufail W, Hutchinson J, Tenorio J, Baliga MP. Assessing patient readiness for the clinical adoption of personalized medicine. Public Health Genomics 2009; 12: 163-169.
26. Rogausch A, Prause D, Schallenberg A, Brockmoller J, Himmel W. Patients' and physicians'perspectives on pharmacogenetic testing. Pharmacogenomics 2006; 7: 49-59.
27. Trosman JR, Van Bebber SL, Phillips KA. Coverage policy development for personalized medicine: private payer perspectives on developing policy for the 21-gene assay. J Oncol Pract 2010; 6: 238-242.
28. Jorgensen AL, Hughes DA, Hanson A, van Eker D, Toh CH, Pirmohamed M et al. Adherence and variability in warfarin dose requirements: assessment in a prospective cohort. Pharmacogenomics 2013; 14: 151-163.
29. Nielsen-Bohlman L. Institute of Medicine (US). Committee on Health Literacy. Health Literacy: A Prescription to End Confusion. National Academies Press: Washington, DC, 2004, xix, p 345.
30. Galesic M, Garcia-Retamero R. Statistical numeracy for health: a cross-cultural comparison with probabilistic national samples. Arch Intern Med 2010; 170: 462-468.